Physician profile
James E Mckendree
NPI 1992700504
$8,798.01
in general payments reported to CMS, 2019-2025
38 companies · $1,685 in 2025
The $1,685 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $232 · 2021: $714 · 2022: $625 · 2023: $2,163 · 2024: $3,268 · 2025: $1,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,115.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,323.03 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,196.70 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $642.65 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $620.22 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $568.55 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $518.59 | 2022-2025 | Xifaxan, Trulance |
| Pfizer INC. | $362.52 | 2021-2024 | |
| Amgen INC. | $341.00 | 2021-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $255.41 | 2020-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $215.97 | 2024-2025 | |
| Exact Sciences Corporation | $201.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.46 | 2022-2024 | Jardiance |
| Astellas Pharma US INC | $140.74 | 2020-2024 | Veozah |
| Abbott Laboratories | $124.35 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Vifor Pharma, INC. | $122.10 | 2020-2023 | Veltassa |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $108.99 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $99.65 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $98.90 | 2023-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| E.R. Squibb & Sons, L.L.C. | $72.31 | 2021-2024 | Eliquis |
| Tactile Systems Technology INC | $61.00 | 2022-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.11 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $50.35 | 2022 | |
| Novartis Pharmaceuticals Corporation | $48.21 | 2023-2025 | |
| Axsome Therapeutics, INC. | $47.99 | 2025 | Auvelity |
| Boston Scientific Corporation | $41.62 | 2025 | Watchman Flx, Axonics |
| Stryker Corporation | $39.06 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Esperion Therapeutics, INC. | $32.75 | 2021-2024 | Nexletol |
| Amarin Pharma, INC. | $31.23 | 2022 | |
| Corcept Therapeutics | $30.70 | 2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $24.48 | 2024 | Keveyis |
| Philips North America LLC | $21.47 | 2025 | Vest Therapy Und |
| Supernus Pharmaceuticals, INC. | $20.22 | 2025 | Qelbree |
| Allergan, INC. | $19.20 | 2022 | |
| Currax Pharmaceuticals LLC | $17.62 | 2025 | Onzetra Xsail, Contrave |
| Verona Pharma, INC. | $17.35 | 2025 | Ohtuvayre |
| Sage Therapeutics, LLC | $15.22 | 2025 | Zurzuvae |
| Medtronic, INC. | $14.91 | 2024 | Intellis Adaptivestim |
| Biohaven Pharmaceuticals, INC. | $14.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mckendree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.